-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5

Benzinga·08/14/2026 20:24:33
語音播報
Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.